What is the recommended treatment for community-acquired pneumonia (CAP)?

Community-Acquired Pneumonia Treatment

Outpatient Management (Previously Healthy Adults)

Amoxicillin 1 g orally three times daily for 5–7 days is the first-line therapy for previously healthy adults without comorbidities. 1 This regimen retains activity against 90–95% of Streptococcus pneumoniae isolates, including many penicillin-resistant strains, and provides superior pneumococcal coverage compared with oral cephalosporins. 1

• Doxycycline 100 mg orally twice daily serves as an acceptable alternative when amoxicillin is contraindicated, offering coverage of both typical bacterial pathogens and atypical organisms (Mycoplasma, Chlamydophila, Legionella). 1

• Macrolide monotherapy (azithromycin or clarithromycin) should only be used when local pneumococcal macrolide resistance is documented to be <25%. 1 In most U.S. regions, resistance is 20–30%, making macrolide monotherapy unsafe as first-line therapy. 1

Outpatient Management (Adults with Comorbidities)

For patients with comorbidities (COPD, diabetes, chronic heart/liver/renal disease, malignancy, or recent antibiotic use within 90 days), combination therapy is required. 1

• Preferred regimen: Amoxicillin-clavulanate 875/125 mg orally twice daily plus azithromycin (500 mg day 1, then 250 mg daily for days 2–5) or doxycycline 100 mg twice daily. 1

• Alternative: Respiratory fluoroquinolone monotherapy (levofloxacin 750 mg daily or moxifloxacin 400 mg daily) is reserved for patients with β-lactam allergy or when combination therapy is contraindicated, acknowledging FDA warnings about serious adverse events (tendon rupture, peripheral neuropathy, aortic dissection). 1

Hospitalized Patients (Non-ICU)

Two equally effective regimens exist with strong recommendations and high-quality evidence: 1

• β-lactam plus macrolide combination: Ceftriaxone 1–2 g IV daily plus azithromycin 500 mg daily (IV or oral), providing coverage for typical bacterial pathogens (S. pneumoniae, H. influenzae, M. catarrhalis) and atypical organisms (Mycoplasma, Chlamydophila, Legionella). 1

• Respiratory fluoroquinolone monotherapy: Levofloxacin 750 mg IV daily or moxifloxacin 400 mg IV daily. 1 Systematic reviews demonstrate fewer clinical failures and treatment discontinuations compared to β-lactam/macrolide combinations. 1

• For penicillin-allergic patients, respiratory fluoroquinolone is the preferred alternative. 1

Severe CAP Requiring ICU Admission

Combination therapy is mandatory for all ICU patients; β-lactam monotherapy is linked to higher mortality in critically ill individuals. 1

• Preferred ICU regimen: Ceftriaxone 2 g IV daily (or cefotaxime 1–2 g IV every 8 hours or ampicillin-sulbactam 3 g IV every 6 hours) plus azithromycin 500 mg IV daily or a respiratory fluoroquinolone (levofloxacin 750 mg IV daily or moxifloxacin 400 mg IV daily). 1

• For penicillin-allergic ICU patients: Aztreonam 2 g IV every 8 hours plus a respiratory fluoroquinolone. 1

Special Pathogen Coverage (Risk-Based Only)

Pseudomonas aeruginosa Coverage

Add antipseudomonal therapy ONLY when specific risk factors are present: 1

• Structural lung disease (bronchiectasis, cystic fibrosis)
• Recent hospitalization with IV antibiotics within 90 days
• Prior respiratory isolation of P. aeruginosa
• Chronic broad-spectrum antibiotic exposure (≥7 days in past month) 1

Antipseudomonal regimen: Piperacillin-tazobactam 4.5 g IV every 6 hours or cefepime 2 g IV every 8 hours plus ciprofloxacin 400 mg IV every 8 hours or levofloxacin 750 mg IV daily plus an aminoglycoside (gentamicin or tobramycin 5–7 mg/kg IV daily) for dual coverage. 1

MRSA Coverage

Add MRSA therapy ONLY when specific risk factors are present: 1

• Prior MRSA infection or colonization
• Recent hospitalization with IV antibiotics
• Post-influenza pneumonia
• Cavitary infiltrates on imaging 1

MRSA regimen: Vancomycin 15 mg/kg IV every 8–12 hours (target trough 15–20 µg/mL) or linezolid 600 mg IV every 12 hours, added to the base CAP regimen. 1

Duration of Therapy

Treat for a minimum of 5 days and continue until the patient is afebrile for 48–72 hours with no more than one sign of clinical instability. 1, 2, 3

• Typical duration for uncomplicated CAP: 5–7 days. 1, 2, 3

• Extended duration (14–21 days) is required ONLY for: Legionella pneumophila, Staphylococcus aureus, or Gram-negative enteric bacilli. 1

• Three-day treatment may be considered for non-severe or moderate CAP in patients who achieve clinical stability by day 3. 2, 4

Transition from IV to Oral Therapy

Switch from IV to oral antibiotics when ALL of the following stability criteria are met: 1

• Temperature ≤37.8°C
• Heart rate ≤100 bpm
• Respiratory rate ≤24 breaths/min
• Systolic blood pressure ≥90 mmHg
• Oxygen saturation ≥90% on room air
• Ability to maintain oral intake
• Normal mental status 1

This transition typically occurs by hospital day 2–3. 1

Oral step-down options: Amoxicillin 1 g three times daily plus azithromycin 500 mg daily (or azithromycin alone after 2–3 days of IV therapy). 1

Critical Timing Considerations

Administer the first antibiotic dose immediately upon diagnosis, ideally while still in the emergency department. 1, 5 Delayed administration beyond 8 hours increases 30-day mortality by 20–30% in hospitalized patients. 1

Diagnostic Testing (Hospitalized Patients)

Obtain blood cultures and sputum Gram stain/culture BEFORE initiating antibiotics in all hospitalized patients to enable pathogen-directed therapy and safe de-escalation. 1, 6

• Urine antigen testing for Legionella pneumophila serogroup 1 should be considered in severe CAP or ICU patients. 1, 7

Common Pitfalls to Avoid

• Never use macrolide monotherapy in hospitalized patients or those with comorbidities, as it fails to cover typical pathogens and leads to treatment failure. 1

• Avoid macrolide monotherapy in areas where pneumococcal macrolide resistance exceeds 25% (most of the United States), as this increases risk of breakthrough bacteremia and treatment failure. 1

• Do not add broad-spectrum antipseudomonal or MRSA agents routinely; restrict their use to patients with documented risk factors to avoid unnecessary resistance and adverse effects. 1

• Avoid indiscriminate fluoroquinolone use in uncomplicated outpatient CAP due to FDA warnings about serious adverse events and resistance concerns. 1

• Do not extend therapy beyond 7–8 days in responding patients without specific indications, as longer courses increase antimicrobial resistance risk without improving outcomes. 1, 3

Follow-Up and Monitoring

• Outpatient review at 48 hours (or sooner if symptoms worsen) to assess response to therapy, oral intake, and medication adherence. 1

• Routine follow-up at 6 weeks for all patients; chest radiograph only for those with persistent symptoms, abnormal physical findings, or high risk for underlying malignancy (e.g., smokers >50 years). 1

• In hospitalized patients, monitor temperature, respiratory rate, pulse, blood pressure, and oxygen saturation at least twice daily to detect early deterioration. 1

• If no clinical improvement by day 2–3, obtain repeat chest radiograph, inflammatory markers (CRP, white blood cell count), and additional microbiologic specimens to evaluate for complications such as pleural effusion, empyema, or resistant organisms. 1

Severity Assessment Tools

Use validated severity scores (Pneumonia Severity Index or CURB-65) together with clinical judgment to determine hospitalization need. 6, 7

• PSI classes I–III: Appropriate for outpatient care
• PSI classes IV–V: Consider hospitalization 7
• CURB-65 score ≥2: Hospital admission recommended 7

ICU admission is indicated when ANY ONE major criterion (septic shock requiring vasopressors or respiratory failure requiring mechanical ventilation) OR ≥3 minor criteria are met. 1